A. Cerebellum B. Cerebral cortex C. Hypothalamus D. Amygdala E. Unsure

A. Methylphenidate and dextroamphetamine effectively treat EDS but have risk of dependence and tolerance B. These two medications have a “strong” recommendation for treatment of adult narcolepsy by the current narcolepsy clinical practice guidelines. C. Methylphenidate and dextroamphetamine are first-line agents due to effectiveness D. Their mechanisms of action involve replacement of hypocretin E. Unsure

A. Excessive daytime sleepiness B. Bilateral tremor C. Cataplexy D. Sleep paralysis E. Unsure

A. Methylphenidate B. Armodafinil C. Solriamfetol D. Sodium oxybate E. Unsure

A. Improved quality of life B. Lower healthcare costs C. Lower lifetime income D. Lower work absenteeism E. Unsure

A. 37.5 mg once daily B. 75 mg once daily C. 150 mg once daily D. 225 mg once daily E. Unsure

A. Modafinil B. Sodium oxybate C. Methylphenidate D. Solriamfetol E. Unsure

A. Excessive daytime sleepiness for at least 3 months and absence of cataplexy B. Excessive daytime sleepiness for at least 3 months, cerebrospinal fluid hypocretin concentrations > 110 pg/mL, and MSLT with sleep latency < 8 minutes with 2 SOREMPs C. Excessive daytime sleepiness for at least 3 months, cerebrospinal fluid hypocretin concentrations ≤ 110 pg/mL D. Excessive daytime sleepiness for at least 3 months, cerebrospinal fluid hypocretin concentrations ≤ 110 pg/ml, and presence of cataplexy E. Unsure

A. Solriamfetol – stimulates gamma aminobutyric acid B (GABAB) and its own GHB receptors B. Sodium oxybate – Inhibition of dopamine and norepinephrine reuptake C. Pitolisant – histamine 3 receptor inverse agonist/antagonist D. Methylphenidate – hypocretin receptor agonist E. Unsure

A. EDS, cataplexy, and quality of life B. EDS, cataplexy, and disease severity C. Cataplexy, disease severity, and quality of life D. EDS, disease severity, and quality of life E. Unsure